Clinical Trial Update: Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a single injection of REGN475/SAR164877 for vertebral fracture pain was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Back Pain
• Vertebral Compression Fracture

Drugs mentioned

• REGN475 (SAR164877) (SAR164877)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Back Pain | Phase 2 | Status: TERMINATED